Iskedjian M - Search Results

1

Economic evaluation of a new acellular vaccine for pertussis in Canada.

Iskedjian M, Einarson TR, O'Brien BJ, De Serres JG, Gold R, Gemmill IM, Milkovich N, Rosner A. Iskedjian M, et al. Pharmacoeconomics. 2001;19(5 Pt 2):551-63. doi: 10.2165/00019053-200119050-00009. Pharmacoeconomics. 2001. PMID: 11465300

2

Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.

Iskedjian M, Einarson TR. Iskedjian M, et al. Pharmacoeconomics. 2003;21(2):115-27. doi: 10.2165/00019053-200321020-00004. Pharmacoeconomics. 2003. PMID: 12515573

3

Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.

Iskedjian M, Walker JH, De Serres G, Einarson TR. Iskedjian M, et al. Paediatr Drugs. 2005;7(2):123-36. doi: 10.2165/00148581-200507020-00005. Paediatr Drugs. 2005. PMID: 15871632

4

Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis.

Iskedjian M, De Serres G, Einarson TR, Walker JH. Iskedjian M, et al. Vaccine. 2010 Jan 8;28(3):714-23. doi: 10.1016/j.vaccine.2009.10.079. Epub 2009 Nov 4. Vaccine. 2010. PMID: 19895923

5

Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature.

Agro KE, Bradley CA, Mittmann N, Iskedjian M, Ilersich AL, Einarson TR. Agro KE, et al. Among authors: iskedjian m. Pharmacoeconomics. 1997 Jan;11(1):75-88. doi: 10.2165/00019053-199711010-00009. Pharmacoeconomics. 1997. PMID: 10165529

6

Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.

Einarson TR, Addis A, Iskedjian M. Einarson TR, et al. Among authors: iskedjian m. Pharmacoeconomics. 1997 Aug;12(2 Pt 2):286-96. doi: 10.2165/00019053-199712020-00019. Pharmacoeconomics. 1997. PMID: 10170453 Clinical Trial.

7

Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).

Iskedjian M, Trakas K, Bradley CA, Addis A, Lanctôt K, Kruk D, Ilersich AL, Einarson TR. Iskedjian M, et al. Pharmacoeconomics. 1997 Dec;12(6):685-94. doi: 10.2165/00019053-199712060-00008. Pharmacoeconomics. 1997. PMID: 10175980

8

Cost of glaucoma in Canada: analyses based on visual field and physician's assessment.

Iskedjian M, Walker J, Vicente C, Trope GE, Buys Y, Einarson TR, Covert D. Iskedjian M, et al. J Glaucoma. 2003 Dec;12(6):456-62. doi: 10.1097/00061198-200312000-00002. J Glaucoma. 2003. PMID: 14646678

9

Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event.

Iskedjian M, Walker JH, Gray T, Vicente C, Einarson TR, Gehshan A. Iskedjian M, et al. Mult Scler. 2005 Oct;11(5):542-51. doi: 10.1191/1352458505ms1211oa. Mult Scler. 2005. PMID: 16193892

10

Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis.

Einarson TR, Granton JT, Vicente C, Walker J, Engel G, Iskedjian M. Einarson TR, et al. Among authors: iskedjian m. Can Respir J. 2005 Nov-Dec;12(8):419-25. doi: 10.1155/2005/719451. Can Respir J. 2005. PMID: 16331313 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters